Epidermal Growth Factor Receptor Inhibitor Database
|
|
|
|
|
|
|
|
|
|
|
| Experimental Information | |
| Enzymatic Activity | |
| Molecule Id | EGIN0004377 |
| PMID | 22703543 |
| Assay Used | Cellular assay |
| Experimently Validated | Yes |
| EGFR (IC50) | - |
| HER2 (IC50) | - |
| HER4 (IC50) | - |
| Mutant L858R (IC50) | - |
| Mutant T790M (IC50) | - |
| Double Mutant (IC50) | - |
| Average ERBB2 and ERBB1 (IC50) | - |
| Inhibition EGFR (%) | - |
| Inhibitory Concentration | - |
| Inhibition HER2 (%) | - |
| Inhibitory Concentration | - |
| Ki (EGFR) | - |
| Ki (HER2) | - |
| Ki (HER4) | - |
| Kd (EGFR) | - |
| Kd (L858R) | - |
| Kd (T790M) | - |
| Kd (L858R/T790M) | - |
| Kd (Other mutation) | - |
| Note | The paper describes the Efficacy of everolimus, a novel mTOR inhibitor,against basal-like triple-negative breast cancer cells |
| Extra | - |
| Cellular Activity | ||||||||||||||
| S.No. | Cell Line | Desp. | IC50 | IC80 | ED50 | GI50 | GI90 | EC50 | Kd | Inhibition (%) | Inhibitory Conc. | |||
| 1 | BT20 | - | 65.7 nM | - | - | - | - | - | - | - | - | |||
| 2 | BT549 | - | 1.6 nM | - | - | - | - | - | - | - | - | |||
| 3 | HCC1937 | - | > 200 nM | - | - | - | - | - | - | - | - | |||
| 4 | HCC38 | - | 76.4 nM | - | - | - | - | - | - | - | - | |||
| 5 | Hs578t | - | 1.6 nM | - | - | - | - | - | - | - | - | |||
| 6 | MDA-MB-157 | - | > 200 nM | - | - | - | - | - | - | - | - | |||
| 7 | MDA-MB-231 | - | > 200 nM | - | - | - | - | - | - | - | - | |||
| 8 | MDA-MB-436 | - | > 200 nM | - | - | - | - | - | - | - | - | |||
| 9 | MDA-MB-468 | - | 0.7 nM | - | - | - | - | - | - | - | - | |||
| Activity against Receptor | |
| EGFR | Yes |
| HER2 | Yes |
| HER4 | - |
| Wild type | Yes |
| Mutant | - |
| Inhibitor Binding | |
| EGFR | - |
| HER2 | - |
| HER4 | - |